Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1435003

USP

6α-Methylprednisolone

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

11β,17α,21-trihydroxy-6α-méthyl-1,4-pregnadiène-3,20-dione, 6α-méthyl-11β,17α,21-trihydroxy-1,4-pregnadiène-3,20-dione

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C22H30O5
Numéro CAS:
83-43-2
Poids moléculaire :
374.47
Numéro Beilstein :
2340300
Numéro MDL:
MFCD00010591
Code UNSPSC :
41116107
ID de substance PubChem :
329750457
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

methylprednisolone

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

Clé InChI

VHRSUDSXCMQTMA-PJHHCJLFSA-N

Informations sur le gène

human ... NR3C1(2908)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Methylprednisolone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Methylprednisolone Sodium Succinate for Injection
  • Methylprednisolone Tablets

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1437009

Methylprednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard

M1750000

6α-Methylprednisolone, European Pharmacopoeia (EP) Reference Standard

M1755200

Methylprednisolone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard

M1755220

Methylprednisolone hydrogen succinate for performance test, European Pharmacopoeia (EP) Reference Standard

M1755000

Methylprednisolone acetate, European Pharmacopoeia (EP) Reference Standard

1436006

Methylprednisolone acetate, United States Pharmacopeia (USP) Reference Standard

PHR1718

Methylprednisolone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001759

Methylprednisolone hydrogen succinate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001736

Methylprednisolone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001760

Methylprednisolone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001799

6α-Methylprednisolone, European Pharmacopoeia (EP) Reference Standard

1435036

Methylprednisolone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1435014

Methylprednisolone Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP248

6α-Methylprednisolone, British Pharmacopoeia (BP) Reference Standard

BP249

Methylprednisolone acetate, British Pharmacopoeia (BP) Reference Standard

BP572

Deltamedrane, British Pharmacopoeia (BP) Reference Standard

1437042

Methyl Prednisolone Hemisuccinate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1437020

Methylprednisolone Hemisuccinate Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR3043

Methylprednisolone Related Compound C, pharmaceutical secondary standard, certified reference material

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360FD,H373

Classification des risques

Repr. 1B - STOT RE 2

Organes cibles

Adrenal gland,Immune system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 2

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 5

1 of 5

Methylprednisolone Acetate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1718

Methylprednisolone Acetate

Dowex 1X8 chloride form chloride form, 100-200 mesh

Supelco

217425

Dowex 1X8 chloride form

Prednisolone ≥99%

Sigma-Aldrich

P6004

Prednisolone

Dexaméthasone powder, BioReagent, suitable for cell culture, ≥97%

Sigma-Aldrich

D4902

Dexaméthasone

Dexaméthasone ≥98% (HPLC), powder

Sigma-Aldrich

D1756

Dexaméthasone

Ornulf Paulsen et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(29), 3221-3228 (2014-07-09)
Corticosteroids are frequently used in cancer pain management despite limited evidence. This study compares the analgesic efficacy of corticosteroid therapy with placebo. Adult patients with cancer receiving opioids with average pain intensity ≥ 4 (numeric rating scale [NRS], 0 to
M Toledano et al.
Neurology, 82(18), 1578-1586 (2014-04-08)
To evaluate a trial of immunotherapy as an aid to diagnosis in suspected autoimmune epilepsy. We reviewed the charts of 110 patients seen at our autoimmune neurology clinic with seizures as a chief complaint. Twenty-nine patients met the following inclusion
Amy L Samuels et al.
British journal of haematology, 165(1), 57-66 (2014-01-25)
Drug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children. Up to 25% of patients with T-cell ALL (T-ALL) develop resistance to chemotherapeutic agents, particularly to glucocorticoids (GCs), a class of drug to
Robert J Fox et al.
Neurology, 82(17), 1491-1498 (2014-04-01)
RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. Eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. Patients
Tyree H Kiser et al.
American journal of respiratory and critical care medicine, 189(9), 1052-1064 (2014-03-13)
Studies evaluating corticosteroid (CS) dosing for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have largely excluded patients admitted directly to the intensive care unit (ICU), and none have evaluated the effect of CS dosing regimens
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique